Press Releases (-) Any 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 Reset 2023 Fri, 27/01/2023 - 01:14 argenx Receives Notification of PDUFA Date Extension for SC Efgartigimod Mon, 16/01/2023 - 13:18 argenx Announces Extraordinary General Meeting of Shareholders on February 27, 2023 to Appoint Steve Krognes as Non-Executive Director Mon, 09/01/2023 - 00:58 argenx Highlights 2023 Strategic Priorities Across Immunology Pipeline Tue, 03/01/2023 - 02:52 argenx to Present at 41st Annual J.P. Morgan Healthcare Conference 2022 Mon, 12/12/2022 - 05:05 argenx Appoints Ana Cespedes to Board of Directors Sat, 10/12/2022 - 01:01 argenx to Present Pivotal ADVANCE Trial Data During ASH Plenary Session Highlighting VYVGART® (efgartigimod alfa-fcab) as Potential New Treatment Modality for Immune Thrombocytopenia Wed, 30/11/2022 - 01:36 argenx Enters Into Agreement To Acquire Priority Review Voucher Tue, 22/11/2022 - 08:04 argenx Announces U.S. FDA Acceptance of Biologics License Application for Subcutaneous Efgartigimod in Generalized Myasthenia Gravis with Priority Review Mon, 07/11/2022 - 00:49 argenx to Present at Upcoming Investor Conferences Fri, 28/10/2022 - 13:06 argenx announces Extraordinary General Meeting of Shareholders on December 12, 2022 Thu, 27/10/2022 - 00:47 argenx Reports Third Quarter 2022 Financial Results and Provides Business Update Thu, 20/10/2022 - 01:00 argenx to Report Third Quarter 2022 Financial Results and Business Update on October 27, 2022 Pagination Current page 1 Página 2 Página 3 Página 4 Página 5 Página 6 Página 7 Página 8 Página 9 … Next page Next › Last page Last »